BIOGEN INC (BIIB) Stock Overview
USA - NASDAQ:BIIB - US09062X1037 - Common Stock
BIIB Key Statistics, Chart & Performance
The current stock price of BIIB is 154.05 USD. In the past month the price increased by 13.66%. In the past year, price decreased by -13.89%.
BIIB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.74 | 406.64B | ||
| AMGN | AMGEN INC | 13.49 | 158.34B | ||
| GILD | GILEAD SCIENCES INC | 14.67 | 140.93B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.78 | 103.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.83 | 62.06B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.25B | ||
| ARGX | ARGENX SE - ADR | 85 | 48.22B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.56 | 37.84B | ||
| INSM | INSMED INC | N/A | 33.46B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.28B | ||
| NTRA | NATERA INC | N/A | 23.38B | ||
| GMAB | GENMAB A/S -SP ADR | 16.09 | 20.50B |
Related stock screener links
About BIIB
Company Profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Company Info
BIOGEN INC
225 Binney Street
Cambridge MASSACHUSETTS 02142 US
CEO: Michel Vounatsos
Employees: 7605
Phone: 17814642000
BIOGEN INC / BIIB FAQ
What is the stock price of BIOGEN INC today?
The current stock price of BIIB is 154.05 USD. The price decreased by -3.65% in the last trading session.
What is the ticker symbol for BIOGEN INC stock?
The exchange symbol of BIOGEN INC is BIIB and it is listed on the Nasdaq exchange.
On which exchange is BIIB stock listed?
BIIB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOGEN INC stock?
42 analysts have analysed BIIB and the average price target is 173.2 USD. This implies a price increase of 12.43% is expected in the next year compared to the current price of 154.05. Check the BIOGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOGEN INC worth?
BIOGEN INC (BIIB) has a market capitalization of 22.59B USD. This makes BIIB a Large Cap stock.
How many employees does BIOGEN INC have?
BIOGEN INC (BIIB) currently has 7605 employees.
What are the support and resistance levels for BIOGEN INC (BIIB) stock?
BIOGEN INC (BIIB) has a support level at 139.76. Check the full technical report for a detailed analysis of BIIB support and resistance levels.
Is BIOGEN INC (BIIB) expected to grow?
The Revenue of BIOGEN INC (BIIB) is expected to grow by 0.4% in the next year. Check the estimates tab for more information on the BIIB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOGEN INC (BIIB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BIIB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BIIB, evaluating the profitability, health, valuation and growth aspects
- BIOGEN INC (BIIB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOGEN INC (BIIB) Sales and EPS estimates to see what analysts future expectations are.
- BIOGEN INC (BIIB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOGEN INC (BIIB) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOGEN INC (BIIB) Stock Chart to make your own analysis
- BIOGEN INC (BIIB) Latest news and press-releases to stay up to date.
Does BIOGEN INC (BIIB) stock pay dividends?
BIIB does not pay a dividend.
When does BIOGEN INC (BIIB) report earnings?
BIOGEN INC (BIIB) will report earnings on 2025-10-22, before the market open.
What is the Price/Earnings (PE) ratio of BIOGEN INC (BIIB)?
The PE ratio for BIOGEN INC (BIIB) is 9.62. This is based on the reported non-GAAP earnings per share of 16.01 and the current share price of 154.05 USD. Check the full fundamental report for a full analysis of the valuation metrics for BIIB.
What is the Short Interest ratio of BIOGEN INC (BIIB) stock?
The outstanding short interest for BIOGEN INC (BIIB) is 3.5% of its float. Check the ownership tab for more information on the BIIB short interest.
BIIB Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to BIIB. When comparing the yearly performance of all stocks, BIIB turns out to be only a medium performer in the overall market: it outperformed 49.24% of all stocks.
BIIB Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BIIB. While BIIB belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
BIIB Financial Highlights
Over the last trailing twelve months BIIB reported a non-GAAP Earnings per Share(EPS) of 16.01. The EPS decreased by -3.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.31% | ||
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| Debt/Equity | 0.36 |
BIIB Forecast & Estimates
42 analysts have analysed BIIB and the average price target is 173.2 USD. This implies a price increase of 12.43% is expected in the next year compared to the current price of 154.05.
For the next year, analysts expect an EPS growth of -1.72% and a revenue growth 0.4% for BIIB